EFFECTIVENESS OF DAPAGLIFLOZIN IN PATIENTS WITH CHRONIC HEART FAILURE

СHF is a chronic progressive disease. Today in the world there are approximately 64 million patients with CHF. The disease is associated with significant morbidity and mortality. CHF is the leading cause of hospital admissions among people over 65 years of age, placing a significant burden on the health care system and economic burden. Experts identify several main categories of heart failure, using the LVEF assessment as an indicator of heart contractility: heart failure with low EF (LVEF ≤ 40%), HF with moderately reduced EF (LVEF 41-49%) and HF with preserved EF (LVEF ≥ 50%). Approximately half of all patients with CHF have HFrEF or HFpEF, a population of patients for whom a limited set of therapeutic options are currently available. Тhanks to effect on prognosis and symptoms in patients  with CHF with low EF (LVEF ≤ 40%), a favorable safety profile and ease of use (reception 1 time / day and no dose titration necessary), dapagliflozin may be considered as an addition to the standard therapy to reduce the severity of symptoms, improve the prognosis of survival incidence and reduction in the number of future hospitalizations in connection with CHF.